Stellar Pharmaceuticals-B Rises Nearly 3% Amid Asset Sale Agreement with Servier for Ivosidenib Business

　　CStone Pharmaceuticals-B(02616) Once rose over 4% during trading, currently up 2.75%, at HK$2.24, with a turnover of HK$22.3932 million.

CStone Pharmaceuticals announced that on December 21, CStone Pharmaceuticals (Suzhou), a wholly-owned subsidiary of the company, entered into an asset purchase agreement with Les Laboratoires Servier. According to the agreement, CStone will sell and Servier will purchase CStone's Ivosidenib business and any associated goodwill (including transferred assets) for a cash consideration of up to 50 million US dollars.

Editor: Lu Yujun